A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk.

Authors: Jianhui Chen, Yiming Su, Rong Liu, Ru Chen, Shaoxing Zhu, Qianyi Qiu

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.tps895

Source: Full article

TPS895